1 Reason Novo Nordisk (NVO) Is 1 of the Best Healthcare Stocks You Can Buy Today
Novo Nordisk is leading the race to get an oral weight loss GLP-1 drug approved. It needs to…
Wall Street rises to its first gain in 4 days
NEW YORK (AP) — U.S. stocks climbed Friday and trimmed their losses for the week after a report…
How the ‘Ozempic effect’ is reshaping the global economy
Michael Siluk/Alamy The new wave of weight-loss drugs has taken the world by storm. From Novo Nordisk’s Ozempic…
2 Undervalued Healthcare Stocks to Buy in 2025 and Hold for Decades
The overall stock market keeps reaching new heights, but some of its components are having a lousy year.…
Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets
The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative…
Weight-loss drugs becoming better value for money, says watchdog
Popular GLP-1 weight-loss injections are now delivering greater value, according to a new report by a leading pharmaceutical…
Is LLY Underperforming the Healthcare Sector?
With a market cap of $694.9 billion, Eli Lilly and Company (LLY) is a leading global pharmaceutical company headquartered…
Drugmaker halves price of Ozempic for Americans amid Trump crackdown
The maker of Ozempic is halving the price of its weight-loss jabs in the US after Donald Trump…
Gai Kun of Kuaishou Concurrently Heads Keling AI Tech Dept, 360 Announces “All in Agent” Strategy, Tsinghua Team Makes Breakthrough in Quantum Computing
Large Companies: Mafengwo: AI itinerary planning function can automatically generate travel guides for users 36Kr learned that from…
Eli Lilly accused of bribing doctors to prescribe Mounjaro and other drugs
Texas Attorney General Ken Paxton filed a lawsuit against Eli Lilly, accusing the drug maker of bribing doctors…
Health Sector Sees Mixed Developments: Resolutions, Delays, and Innovations
The U.S. Food and Drug Administration announced a resolution to the nation’s saline shortage, a move easing…
ETFs in Focus on Eli Lilly’s Solid Q2 Earnings, Weak Obesity Data
Eli Lilly and Company LLY reported robust second-quarter 2025 results, wherein it beat estimates on both the top…